These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9054961)

  • 1. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
    Smith PJ; Blunt NJ; Desnoyers R; Giles Y; Patterson LH
    Cancer Chemother Pharmacol; 1997; 39(5):455-61. PubMed ID: 9054961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation.
    Smith PJ; Desnoyers R; Blunt N; Giles Y; Patterson LH; Watson JV
    Cytometry; 1997 Jan; 27(1):43-53. PubMed ID: 9000584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
    Patterson LH
    Cancer Metastasis Rev; 1993 Jun; 12(2):119-34. PubMed ID: 8375016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
    De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
    Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
    Fox ME; Smith PJ
    Cancer Res; 1990 Sep; 50(18):5813-8. PubMed ID: 2168281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
    De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC
    Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity.
    Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M
    J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
    Ahn G; Lansiaux A; Goossens JF; Bailly C; Baldeyrou B; Schifano-Faux N; Grandclaudon P; Couture A; Ryckebusch A
    Bioorg Med Chem; 2010 Nov; 18(22):8119-33. PubMed ID: 20961767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
    Ryckebusch A; Garcin D; Lansiaux A; Goossens JF; Baldeyrou B; Houssin R; Bailly C; Hénichart JP
    J Med Chem; 2008 Jun; 51(12):3617-29. PubMed ID: 18507368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J; Catapano CV; Fernandes DJ
    Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ametantrone-amsacrine related hybrids as topoisomerase IIβ poisons and cytotoxic agents.
    Zagotto G; Gianoncelli A; Sissi C; Marzano C; Gandin V; Pasquale R; Capranico G; Ribaudo G; Palumbo M
    Arch Pharm (Weinheim); 2014 Oct; 347(10):728-37. PubMed ID: 25042690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line.
    Smith PJ; Makinson TA
    Cancer Res; 1989 Mar; 49(5):1118-24. PubMed ID: 2537142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells.
    Cheng MH; Yang YC; Wong YH; Chen TR; Lee CY; Yang CC; Chen SH; Yang IN; Yang YS; Huang HS; Yang CY; Huang MS; Chiu HF
    Anticancer Drugs; 2012 Feb; 23(2):191-9. PubMed ID: 22008852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
    Pourpak A; Landowski TH; Dorr RT
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
    Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
    Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.
    Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK
    Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.